U.S. Markets open in 2 hrs 47 mins

Amyris, Inc. (AMRS), Zogenix, Inc. (ZGNX) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Announces Class Actions

NEW YORK, NY / ACCESSWIRE / May 24, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Amyris, Inc. (AMRS)

Class Period: March 15, 2018 - March 19, 2019

Deadline: June 3, 2019

For more info: www.bgandg.com/amrs

The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) Amyris lacked sufficient resources to accurately account for certain transactions; (2) there was a material weakness in Amyris' internal controls over financial reporting; (3) Amyris would be unable to timely file its annual report; and (4) as a result of the foregoing, the defendants' positive statements about Amyris' business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Zogenix, Inc. (ZGNX)

Class Period: February 6, 2019 - April 8, 2019

Deadline: June 11, 2019

For more info: www.bgandg.com/zgnx

The lawsuit alleges that the Company and its executives violated federal securities laws by failing to disclose that: (1) Zogenix's NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (2) consequently, Zogenix's NDA for FINTEPLA was unlikely to gain FDA approval; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX)

Class Period: January 28, 2019 - February 12, 2019

Deadline: June 14, 2019

For more info: www.bgandg.com/trnx

According to the lawsuit, defendants throughout the Class Period allegedly made false and/or misleading statements and/or failed to disclose that: (1) Taronis did not have a contract with the City of San Diego; (2) Taronis and its management had engaged in a scheme to defraud; and (3) that as a result of the foregoing, Taronis' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/545925/Amyris-Inc-AMRS-Zogenix-Inc-ZGNX-Taronis-Technologies-Inc-fka-MagneGas-Applied-Technology-TRNX--Bronstein-Gewirtz-Grossman-LLC-Announces-Class-Actions



View source version on accesswire.com:
https://www.accesswire.com/545925/Amyris-Inc-AMRS-Zogenix-Inc-ZGNX-Taronis-Technologies-Inc-fka-MagneGas-Applied-Technology-TRNX--Bronstein-Gewirtz-Grossman-LLC-Announces-Class-Actions